C Diff Treatment

Researchers found that certain enzymes within a class known as bile salt hydrolases (BSHs) can restrict Clostridioides difficile (C. diff.) colonization by both altering existing bile acids and by creating a new class of bile acids within the gut's microbial environment. The work could lead to 'designer' probiotics that protect against disease by introducing specific BSHs to the gut after antibiotic treatment.

Nitrofurantoin use and a history of malignancy were significantly associated with recurrent infections, which increased during 2019–2020.

With the approval and development of narrow-spectrum antibiotics for the treatment of Clostridioides difficile infection (CDI), the primary endpoint for treatment success of CDI antibiotic treatment trials has shifted from treatment response at end of therapy to sustained response 30 days after completed therapy. The current definition of a successful response to treatment (three or fewer unformed bowel movements [UBMs] per day for 1–2 days) has not been validated, does not reflect CDI management, and could impair assessments for successful treatment at 30 days.

Our study confirms the efficacy of BEZ+SoC for the prevention of rCDI and death in a real-world setting. BEZ should be routinely considered among participants at high risk of rCDI regardless of age, type of CDI therapy (vancomycin vs. fidaxomicin) and number of risk factors.

The incidence of mPDAI-defined remission at week 14 was 31% in the vedolizumab group, compared to 10% in the placebo group.

A live biotherapeutics product used alongside antibiotics can help combat C. difficile infection (CDI).

Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, speaks on current indications for Rebyota (fecal microbiota, live-jslm) in the treatment of recurrent Clostridioides difficile infection (CDI), as well as coverage and access-related implications for the drug.

In-the-last-decade-we-have-started-to-understand-the-critical-components-of-the-gut-microbiome-that-prevent-C-difficile-expansion

Clostridioides difficile infection (CDI) is the second most common health care acquired infection (HAI) and the most common gastrointestinal HAI, with an estimated 365,200 cases reported by the center for disease control in 2017. CDI continues to remain a major cause of inpatient admission an …

Antibiotic therapy was independently associated with adverse drug events in hospitalized older adults with advanced cancer. These findings may inform antibiotic decision-making among palliative care providers.

We conducted a systematic review and meta-analysis to examine the efficacy profiles of metronidazole (MNZ) and vancomycin (VCM) in pediatric and adolescent patients with Clostridioides difficile infection (CDI). A systematic review and meta-analysis was conducted using four electronic databases (Pub …

The WHO warns that there aren't enough new antibiotics in development to fight deadly superbugs as drug resistance rises.

Clostridioides difficile is, worldwide, the leading cause of hospital-acquired infection. Outbreaks are largely related to antibiotic exposure and contact contamination, but little is known about C. difficle infection (CDI) awareness in the nurse population. We conducted a cross-sectio …

The main cause of C. diff infection remains antibiotic use and overuse.

Clostridioides difficile is, worldwide, the leading cause of hospital-acquired infection. Outbreaks are largely related to antibiotic exposure and contact contamination, but little is known about C. difficle infection (CDI) awareness in the nurse population. We conducted a cross-sectio …

Extended Follow-up of Microbiome Therapeutic SER-109 for Recurrent Clostridioides difficile Infection

Colonization with nontoxigenic Clostridioides difficile strain M3 (NTCD-M3) has been demonstrated in susceptible hamsters and humans when administered after vancomycin treatment. NTCD-M3 has also been shown to decrease risk of recurrent C. difficile infection (CDI) in patients following vancomycin t …

While oral vancomycin is mostly safe and well tolerated in the RCTs reviewed here, the efficacy for treating rCDI varies greatly from 19-58.3%, and 50-63% of participants experienced new episodes of rCDI.

Recent use of piperacillin/tazobactam might be associated with a lower risk of CDI recurrence, while recent use of cephalosporins might promote an increased risk. These findings should be considered when treating hospitalized patients.

Clostridioides difficile, or C. difficile for short, is a bacteria that continues to plague our patients. What are the latest treatment updates that you need to be aware of? Dr. Neil Nandi is joined by Dr. Monika Fischer from Indiana University to dive into treatment options and discuss the latest updates.

Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, discusses the standard of care for the prevention and treatment of primary and recurrent Clostridioides difficile infection (CDI).

The Clostridioides difficile Health-related Quality-of-Life Questionnaire responses demonstrated patients handled the situation better with specific investigational treatments.

Gut enzymes within a class known as bile salt hydrolases can restrict Clostridioides difficile.

When the FDA approved Rebyota, a new class of Clostridioides Difficile (C.diff) treatment, Ferring Pharmaceuticals ushered in the first significant breakthrough doctors treating the disease have seen in years. Rebyota falls in the class of therapy known as Fecal Microbiota Transplant, or FMT, a therapy over 60% of treating gastroenterologists believe will dramatically change the paradigm of C.diff treatment in the next five years, according to research from Spherix Global Insights Market Dynamix

Massachusetts [US], March 12 (ANI): Researchers at Brigham and Women’s Hospital (BWH) and Massachusetts General Hospital (MGH), two of the founding institutions of Mass General Brigham, have discovered the metabolic mechanisms Clostridioides difficile uses to quickly invade the gut. The findings point to new ways to prevent and treat the most prevalent infection types and […]

Not all probiotics are created equal. In a new study, researchers found that certain enzymes within a class known as bile salt hydrolases (BSHs) can restrict Clostridioides difficile (C. diff.) colonization by both altering existing bile acids and by creating a new class of bile acids within the gut's microbial environment. The work could lead to "designer" probiotics that protect against disease by introducing specific BSHs to the gut after antibiotic treatment.

A team of investigators from Mass General Brigham's founding members, Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH), has identified metabolic strategies used by Clostridioides ...

Researchers from Brigham and Women’s Hospital and Massachusetts General Hospital identified new targets for small molecule drugs to counter Clostridioides difficile colonization and infection (CDI) in the gut and provide a new approach to rapidly define microbial metabolism for other applications.

SUMMARY: Clostridioides difficile is a gram-positive spore-forming and toxin-producing bacteria that can cause disease ranging from mild diarrhea to severe and even fatal colonic inflammation. It is spread via the fecal-oral route. This infection often occurs after antibiotic use, as antibiotics change the normal gut flora and allows this bacterium to grow and produce its […]

A young woman who dealt with reoccurring Clostridioides difficile (CDI) in a short amount of time recounts her experience and how getting into a clinical trial made the difference in resolving her condition and getting her back to good health and her family.